A phase II, multicenter, open label study to evaluate effectiveness and safety of Ad5CMV-p53 administered by intra-tumoral injections in 39 patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)

Trial Profile

A phase II, multicenter, open label study to evaluate effectiveness and safety of Ad5CMV-p53 administered by intra-tumoral injections in 39 patients with recurrent squamous cell carcinoma of the head and neck (SCCHN)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Sep 2005

At a glance

  • Drugs Contusugene ladenovec (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Sep 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top